JP2008521805A - β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物 - Google Patents

β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物 Download PDF

Info

Publication number
JP2008521805A
JP2008521805A JP2007543114A JP2007543114A JP2008521805A JP 2008521805 A JP2008521805 A JP 2008521805A JP 2007543114 A JP2007543114 A JP 2007543114A JP 2007543114 A JP2007543114 A JP 2007543114A JP 2008521805 A JP2008521805 A JP 2008521805A
Authority
JP
Japan
Prior art keywords
compound
hydroxy
chloro
phenyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521805A5 (enExample
Inventor
マルコム ジョージ テイラー，
バークハード クレンケ，
ピーター ディー． スズダク，
レーザ マジャリ，
Original Assignee
アーテシアン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーテシアン セラピューティクス， インコーポレイテッド filed Critical アーテシアン セラピューティクス， インコーポレイテッド
Publication of JP2008521805A publication Critical patent/JP2008521805A/ja
Publication of JP2008521805A5 publication Critical patent/JP2008521805A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007543114A 2004-11-30 2005-11-08 β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物 Pending JP2008521805A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63159904P 2004-11-30 2004-11-30
US71775605P 2005-09-19 2005-09-19
PCT/US2005/040409 WO2006060122A2 (en) 2004-11-30 2005-11-08 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase

Publications (2)

Publication Number Publication Date
JP2008521805A true JP2008521805A (ja) 2008-06-26
JP2008521805A5 JP2008521805A5 (enExample) 2008-11-06

Family

ID=36218300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543114A Pending JP2008521805A (ja) 2004-11-30 2005-11-08 β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物

Country Status (5)

Country Link
US (1) US20080255134A1 (enExample)
EP (1) EP1833480A2 (enExample)
JP (1) JP2008521805A (enExample)
CA (1) CA2588947A1 (enExample)
WO (1) WO2006060122A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509858A (ja) * 2008-11-25 2012-04-26 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥大性心筋症治療用のホスホジエステラーゼタイプＩＩＩ（ＰＤＥＩＩＩ）インヒビターまたはＣａ２＋感作剤
JP2019521964A (ja) * 2016-05-13 2019-08-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー アドレナリン受容体調節化合物およびその使用方法
JP2021505598A (ja) * 2017-12-06 2021-02-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 心不全およびそれに関連する障害の治療または予防に有用なβ−３アドレナリン受容体のモジュレーター

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
PH12012502411A1 (en) 2005-05-10 2019-07-17 Intermune Inc Method of modulating stress-activated protein kinase system
WO2007042912A2 (en) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
CA2658821C (en) 2006-07-25 2014-10-21 Cephalon, Inc. Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US20080262226A1 (en) * 2006-11-07 2008-10-23 Artesian Therapeutics, Inc. Methods of making compounds having a beta-adrenergic inhibitor and a linker and methods of making compounds having a beta-adrenergic inhibitor, a linker and a phosphodiesterase inhibitor
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
HRP20251029T1 (hr) 2013-07-19 2025-10-24 Boehringer Ingelheim Vetmedica Gmbh Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak
US12091408B2 (en) * 2013-08-30 2024-09-17 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same
PL3106150T3 (pl) 2013-12-04 2022-01-03 Boehringer Ingelheim Vetmedica Gmbh Ulepszone kompozycje farmaceutyczne pimobendanu
WO2015104602A2 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for the preparation of anagliptin and its intermediates thereof
IN2014MU01191A (enExample) 2014-03-29 2015-10-02 Wockhardt Ltd
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
US10919249B2 (en) 2016-02-19 2021-02-16 Albert Mardikian Apparatus for pressing and dehydrating of waste
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
TN2019000290A1 (en) 2017-03-20 2021-05-07 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
BR112022004715A2 (pt) 2019-09-19 2022-06-14 Forma Therapeutics Inc Composições de ativação de piruvato quinase r (pkr)
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283382A (en) * 1975-12-27 1977-07-12 Otsuka Pharmaceut Co Ltd Synthesis of carbostyril derivatives
JPS52108970A (en) * 1976-03-09 1977-09-12 Boehringer Sohn Ingelheim Production of novel aminoalkyl heterocyclic compound
JPS5368775A (en) * 1976-10-05 1978-06-19 Boehringer Sohn Ingelheim 11aryloxyy22mydroxyy33 alkyleneaminopropane
JPS54157558A (en) * 1978-04-13 1979-12-12 Boehringer Mannheim Gmbh Novel carbazolyll*4**oxyypropanolamine derivative*its manufacture and drug containing it and having vasodilatation and*or betaaacceptor occlusion activity
JPS61246162A (ja) * 1985-02-11 1986-11-01 インペリアル・ケミカル・インダストリ−ズ・ピ−エルシ− ジヒドロピリジン、その製造法および該化合物を含有する高血圧治療剤
JPS63183568A (ja) * 1986-09-08 1988-07-28 Teikoku Hormone Mfg Co Ltd ピリダジノン誘導体
JPH035465A (ja) * 1989-06-02 1991-01-11 Teikoku Hormone Mfg Co Ltd 光学活性ピリダジノン誘導体
JPH0386868A (ja) * 1989-06-19 1991-04-11 Teikoku Hormone Mfg Co Ltd ピリダジノン化合物
JPH03141264A (ja) * 1989-08-10 1991-06-17 Glaxo Inc 強心活性およびベータ遮断活性を有するピリダジノン
JPH03178965A (ja) * 1989-09-22 1991-08-02 Glaxo Inc 心臓血管障害の治療に有用なピリドンニトリル
WO2004050657A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
WO2004058726A2 (en) * 2002-12-23 2004-07-15 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1488330A (en) * 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
US4111935A (en) * 1975-01-02 1978-09-05 Smith Kline & French Laboratories Limited 3-chloro-6-phenylpyridazine compounds
DE3023369A1 (de) * 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8323553D0 (en) * 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
JPS6193169A (ja) * 1984-10-12 1986-05-12 Sankyo Co Ltd ピリダジノン誘導体及びその製法
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
NZ234087A (en) * 1989-06-19 1991-08-27 Teikoku Hormone Mfg Co Ltd 2-(3-aryloxy(2-hydroxy-propylamino))-2-methylpropyl- aminophenyl pyridazine derivatives
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5827893A (en) * 1996-03-29 1998-10-27 Lurie; Keith G. Mechanical and pharmacological therapies to treat cardiac arrest
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
JP5258763B2 (ja) * 2007-06-20 2013-08-07 興和株式会社 ５−フェニル−３−ピリダジノン誘導体
US8440666B2 (en) * 2007-10-31 2013-05-14 Nissan Chemical Industries, Ltd. Pyridazinone compounds and P2X7 receptor inhibitors
EP2204366A1 (de) * 2008-12-19 2010-07-07 Bayer CropScience AG Herbizid und insektizid wirksame phenylsubstituierte Pyridazinone

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283382A (en) * 1975-12-27 1977-07-12 Otsuka Pharmaceut Co Ltd Synthesis of carbostyril derivatives
JPS52108970A (en) * 1976-03-09 1977-09-12 Boehringer Sohn Ingelheim Production of novel aminoalkyl heterocyclic compound
JPS5368775A (en) * 1976-10-05 1978-06-19 Boehringer Sohn Ingelheim 11aryloxyy22mydroxyy33 alkyleneaminopropane
JPS54157558A (en) * 1978-04-13 1979-12-12 Boehringer Mannheim Gmbh Novel carbazolyll*4**oxyypropanolamine derivative*its manufacture and drug containing it and having vasodilatation and*or betaaacceptor occlusion activity
JPS61246162A (ja) * 1985-02-11 1986-11-01 インペリアル・ケミカル・インダストリ−ズ・ピ−エルシ− ジヒドロピリジン、その製造法および該化合物を含有する高血圧治療剤
JPS63183568A (ja) * 1986-09-08 1988-07-28 Teikoku Hormone Mfg Co Ltd ピリダジノン誘導体
JPH035465A (ja) * 1989-06-02 1991-01-11 Teikoku Hormone Mfg Co Ltd 光学活性ピリダジノン誘導体
JPH0386868A (ja) * 1989-06-19 1991-04-11 Teikoku Hormone Mfg Co Ltd ピリダジノン化合物
JPH03141264A (ja) * 1989-08-10 1991-06-17 Glaxo Inc 強心活性およびベータ遮断活性を有するピリダジノン
JPH03178965A (ja) * 1989-09-22 1991-08-02 Glaxo Inc 心臓血管障害の治療に有用なピリドンニトリル
WO2004050657A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
WO2004058726A2 (en) * 2002-12-23 2004-07-15 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509858A (ja) * 2008-11-25 2012-04-26 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥大性心筋症治療用のホスホジエステラーゼタイプＩＩＩ（ＰＤＥＩＩＩ）インヒビターまたはＣａ２＋感作剤
JP2019521964A (ja) * 2016-05-13 2019-08-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー アドレナリン受容体調節化合物およびその使用方法
US11173144B2 (en) 2016-05-13 2021-11-16 The Board Of Trustees Of The Leland Stanford Junior University Adrenergic receptor modulating compounds and methods of using the same
JP2021505598A (ja) * 2017-12-06 2021-02-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 心不全およびそれに関連する障害の治療または予防に有用なβ−３アドレナリン受容体のモジュレーター
JP7357617B2 (ja) 2017-12-06 2023-10-06 アリーナ ファーマシューティカルズ， インコーポレイテッド 心不全およびそれに関連する障害の治療または予防に有用なβ－３アドレナリン受容体のモジュレーター

Also Published As

Publication number Publication date
WO2006060122A3 (en) 2007-03-22
EP1833480A2 (en) 2007-09-19
WO2006060122A9 (en) 2006-08-17
WO2006060122A2 (en) 2006-06-08
CA2588947A1 (en) 2006-06-08
US20080255134A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
JP2008521805A (ja) β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
JP7376556B2 (ja) 心臓状態に対するピリミジンジオン化合物
KR100605140B1 (ko) 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
US7189739B2 (en) Compounds and methods to treat cardiac failure and other disorders
JP2001521926A (ja) 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US7098211B2 (en) Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
US20080090827A1 (en) Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
US20070060748A1 (en) Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
US4517188A (en) 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
US20070117978A1 (en) Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
JP3165935B2 (ja) ３（２ｈ）−ピリダジノン誘導体、その製造法、及びそれを含有する製剤組成物
US20070225308A1 (en) 2-Amino Quinazoline Derivative
CA2727669A1 (fr) Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
JP3499569B2 (ja) 新規複素環式化合物
EP0419286A2 (en) Pyridone nitriles useful in treating cardiovascular disease
US20070066619A1 (en) Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
FR2543952A1 (fr) Composes hydrocarbones heterocycliques appartenant aux series indoliques et leur application pharmacologique
US5153209A (en) Pyridone nitriles useful in treating cardiovascular disease
EP0220104A2 (fr) Dérivés d'amino-5 pentanenitrile, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
FR2649395A1 (fr) Nouveau derive de la dihydro-1,4 pyridine denomme (-) Ÿi1Ÿ(((amino-2 ethoxy)-2 ethoxy) methylŸi1Ÿ) -2 (dichloro-2,3 phenyl)-4 ethoxycarbonyl-3 methoxycarbonyl-5 methyl-6 dihydro-1,4 pyridine, son procede de preparation et les compositions qui le contiennent
CN120271512A (zh) 一种异羟肟酸衍生物及其用途
WO2000061554A1 (fr) Derives de 1-amino ethylindole pour le traitement de l'incontinence urinaire
JP2004155731A (ja) 循環障害による疾病の治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111025

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120329